CytoDyn secures $17.5 million in funding for further development of Leronlimab

CytoDyn Inc. (OTCQB: CYDY) recently closed a financing round, securing $17.5 million in gross proceeds to further develop leronlimab, a groundbreaking humanized monoclonal antibody aimed at the CCR5 receptor. The successful completion of this financing round, with Paulson Investment Company as the placement agent, reflects the strong support from both new and existing investors. This support signals confidence in CytoDyn’s clinical progress and its innovative approach to immuno-oncology, exploring various potential applications for leronlimab.

Robert E. Hoffman, CytoDyn’s CFO, emphasized the significance of this funding in bolstering the company’s financial standing. The proceeds are anticipated to sustain operations until 2027, allowing for the continuous progress of clinical programs and strategic initiatives. The backing received from investors, both old and new, demonstrates faith in the ongoing development of leronlimab and its potential value in oncology. This underscores CytoDyn’s commitment to prudent execution and the creation of long-term value.

The primary use of the proceeds will be to advance CytoDyn’s clinical development projects, such as ongoing and planned trials, engaging with regulatory bodies, and analyzing data. Additionally, funds may be directed towards operational aspects like manufacturing readiness, compliance infrastructure, and general working capital.

For detailed information on CytoDyn’s recent fundraising endeavors, including contract specifics, interested parties are encouraged to refer to the company’s filings with the Securities and Exchange Commission, particularly the Current Report on Form 8-K submitted on March 5, 2026.

CytoDyn specializes in oncology and is dedicated to propelling leronlimab, a cutting-edge humanized monoclonal antibody that targets the CCR5 receptor, pivotal in immune function regulation concerning cancers, infectious diseases, and autoimmune disorders. The company’s commitment to enhancing patient quality of life through therapeutic breakthroughs is evident in its core values of integrity, responsibility, and service. CytoDyn aims to introduce transformative treatments to patients worldwide, guided by a passion for innovation.

Readers should exercise caution with forward-looking statements in this news release, as they are based on current expectations of future events. CytoDyn advises against relying solely on these statements, encouraging a review of the Annual Report on Form 10-K for the fiscal year ending May 31, 2025, for a comprehensive understanding of the company’s risks, uncertainties, and other factors affecting actual results. CytoDyn Inc. does not commit to updating forward-looking statements beyond what is mandated by law.

For more details on CytoDyn and its endeavors, visit the company’s website and stay updated by following its LinkedIn page.